Altimmune Inc expected to post a loss of 36 cents a share - Earnings Preview

Altimmune

09/05/2025 15:24

Altimmune Inc ALT.OQ ALT.O is expected to show a fall in quarterly revenue when it reports  results on May 13 for the period ending March 31 2025

​LSEG's mean analyst estimate for Altimmune Inc is for a loss of 36 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Altimmune Inc is $25.00​, above​ its last closing price of $5.80. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.34
-0.33
-0.33
Met
-0.8
Sep. 30 2024
-0.38
-0.35
-0.32
Beat
9.6
Jun. 30 2024
-0.34
-0.34
-0.35
Missed
-2.6​
Mar. 31 2024
-0.36
-0.37
-0.34
Beat
7.4
​​Dec. 31 2023
-0.56
-0.43
-0.33
Beat
23.9
Sep. 30 2023
-0.41
-0.42
-0.39
Beat
8.1​
Jun. 30 2023
-0.45
-0.46
-0.32
Beat
31.1
Mar. 31 2023
-0.48
-0.48
-0.40
Beat
16.6

This summary was machine generated May 9 at 14:24 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)